Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1990 1
1998 1
2002 1
2007 1
2009 1
2019 1
2020 5
2021 6
2022 5
2023 3
2024 6
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.
Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, Ribas de Almeida AC, Hajek R, Kim K, Grosicki S, Sia H, Bryant A, Pitombeira de Lacerda M, Aparecida Martinez G, Sureda Balarí AM, Sandhu I, Cerchione C, Ganly P, Dimopoulos M, Fu C, Garg M, Abdallah AO, Oriol A, Gatt ME, Cavo M, Rifkin R, Fujisaki T, Mielnik M, Pirooz N, McKeown A, McNamara S, Zhou X, Nichols M, Lewis E, Rogers R, Baig H, Eccersley L, Roy-Ghanta S, Opalinska J, Mateos MV; DREAMM-7 Investigators. Hungria V, et al. N Engl J Med. 2024 Aug 1;391(5):393-407. doi: 10.1056/NEJMoa2405090. Epub 2024 Jun 1. N Engl J Med. 2024. PMID: 38828933 Clinical Trial.
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial.
Hungria V, Hus M, Fu C, Zherebtsova V, Ward C, Ho PJ, Mikulski D, Muronova L, Cerchione C, Loubert A, Bunod L, M'Hari M, Pirooz N, Rogers R, Lin CP, Roy-Ghanta S, Opalinska JB, Purser M, McKeown A, McNamara S, Baig H, Eccersley L, Pompilus F, Mateos MV; DREAMM-7 trial study group. Hungria V, et al. Lancet Haematol. 2025 Aug;12(8):e599-e610. doi: 10.1016/S2352-3026(25)00163-2. Epub 2025 Jul 15. Lancet Haematol. 2025. PMID: 40680752 Clinical Trial.
High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis.
Khwaja J, Bomsztyk J, Mahmood S, Wisniowski B, Shah R, Tailor A, Yong K, Popat R, Rabin N, Kyriakou C, Sive J, Esposti SD, Larkin DFP, Worthington S, Hart A, Dowling E, Correia N, Bygrave C, Rydzewski A, Jamroziak K, Wechalekar AD. Khwaja J, et al. Among authors: bygrave c. Blood Cancer J. 2022 Sep 5;12(9):128. doi: 10.1038/s41408-022-00717-2. Blood Cancer J. 2022. PMID: 36064540 Free PMC article. No abstract available.
COVID-19 and myeloma clinical research - experience from the CARDAMON clinical trial.
Camilleri M, Sive J, Wilson W, Pang G, Jenner R, Phillips E, Popat R, Ramasamy K, Bygrave C, Dadaga T, Streetly M, Cavenagh J, Chapman M, Barrington S, Pike L, Owen R, Clifton-Hadley L, Yong K. Camilleri M, et al. Among authors: bygrave c. Br J Haematol. 2021 Jan;192(1):e14-e16. doi: 10.1111/bjh.17168. Epub 2020 Nov 21. Br J Haematol. 2021. PMID: 33222153 Free PMC article. Clinical Trial. No abstract available.
Sociodemographic Inequalities in Blood Cancer Survival in Wales.
Allen J, Capel R, Withrow D, Hoang J, Thomas R, Smits S, Cox S, Bygrave C. Allen J, et al. Among authors: bygrave c. Stud Health Technol Inform. 2025 May 15;327:1244-1245. doi: 10.3233/SHTI250593. Stud Health Technol Inform. 2025. PMID: 40380698
Real-world efficacy of single-agent belantamab mafodotin in relapsed systemic AL amyloidosis.
Khwaja J, Bomsztyk J, Atta M, Bygrave C, Forbes A, Durairaj S, Fernandes S, Taylor J, Paterson P, Brearton G, Crawley C, Sheehy O, Brown R, Soutar R, Garg M, Rydzewski A, Jamroziak K, Mahmood S, Wechalekar AD. Khwaja J, et al. Among authors: bygrave c. Br J Haematol. 2024 May;204(5):1811-1815. doi: 10.1111/bjh.19286. Epub 2024 Jan 3. Br J Haematol. 2024. PMID: 38171355
30 results